Explore / Clinical trial
Clinical trial

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

Janssen-Cilag Ltd.CompletedPhase 4Started Apr 26, 2021183 enrolledArgentina, Belgium, Bulgaria, Czechia, Finland, Germany, Greece, Hungary, Malaysia, Poland, South Africa, South Korea, Taiwan, Turkey (Türkiye)NCT04829318

Abstract

The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Keywords

Treatment resistant depressionDepressive Disorder, Major

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.